Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cerus Corporation    CERS

CERUS CORPORATION (CERS)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 11/17 10:00:01 pm
3.75 USD   +1.63%
11/07 CERUS CORPORATI : Receives IDE Approval to Initiate Phase III ReCePI..
11/02 CERUS : reports 3Q loss
11/02 CERUS CORPORATI : Reports Third Quarter 2017 Results
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
3.58(c) 3.51(c) 3.63(c) 3.69(c) 3.75(c) Last
748 440 535 305 531 709 649 574 513 594 Volume
-0.56% -1.96% +3.42% +1.65% +1.63% Change
More quotes
Financials ($)
Sales 2017 41,1 M
EBIT 2017 -59,3 M
Net income 2017 -62,1 M
Finance 2017 11,3 M
Yield 2017 -
Sales 2018 51,6 M
EBIT 2018 -51,6 M
Net income 2018 -53,6 M
Finance 2018 42,1 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 10,1x
EV / Sales2018 7,48x
Capitalization 428 M
More Financials
Company
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products.It produces blood system for platelets and plasma.It markets its products under the INTERCEPT brand.The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is... 
More about the company
Surperformance© ratings of Cerus Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CERUS CORPORATION
11/16 CERUS CORPORATION : Receives IDE Approval to Initiate Phase III ReCePI Study
11/09 CERUS : and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEP..
11/09 CERUS : Announces Agreement with Transfusion Center of the Community of Madrid
11/08 CERUS CORPORATION : Receives IDE Approval to Initiate Phase III ReCePI Study
11/07 CERUS CORPORATION : Receives IDE Approval to Initiate Phase III ReCePI Study
11/03 CERUS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
11/02 CERUS : reports 3Q loss
11/02 CERUS CORP : Results of Operations and Financial Condition, Financial Statements..
11/02 CERUS CORPORATION : Reports Third Quarter 2017 Results
11/02 CERUS : Announces National German Reimbursement for Pathogen Inactivated Platele..
More news
Sector news : Medical Devices & Implants
11/13 Poor earnings updates keep European shares at seven-week low
11/13 SONOVA : misses sales, profit forecasts as U.S. overhaul bites
11/12 FISHER & PAYKEL HEALTHCARE : & Paykel says UK court rules rival Resmed's patent ..
11/03 ESSILOR INTERNATIONAL : EU regulators suspend Luxottica, Essilor probe, await da..
11/03DJESSILOR INTERNATIONAL : EU Regulator Has Suspended Essilor, Luxottica Probe -Reu..
More sector news : Medical Devices & Implants
News from SeekingAlpha
11/07 Planned equity offering roundup - healthcare
11/03 Midday Gainers / Losers
11/03 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
11/02 Cerus' (CERS) CEO Obi Greenman on Q3 2017 Results - Earnings Call Transcript
11/02 Cerus beats by $0.03, misses on revenue
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | 4-Traders
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 6,33 $
Spread / Average Target 69%
EPS Revisions
Managers
NameTitle
William Mariner Greenman President, Chief Executive Officer & Director
Daniel N. Swisher Chairman
Suzanne Margerum Vice President-Manufacturing & Operations
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Laurence M. Corash Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CERUS CORPORATION-13.79%428
STRYKER CORPORATION29.71%58 157
SMITH & NEPHEW8.68%15 313
WRIGHT MEDICAL GROUP NV7.92%2 604
JAPAN LIFELINE CO., LTD.122.13%2 089
GLAUKOS CORP-22.89%914